Candel Therapeutics (CADL) Other financing activities (2020 - 2025)
Candel Therapeutics (CADL) posted Other financing activities of $4000.0 for Q4 2025, down 80.0% sequentially from $20000.0 in Q3 2025, and down 98.92% YoY from $370000.0 in Q4 2024.
Candel Therapeutics (CADL) Other financing activities (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Other financing activities for 5 years, with the latest figure at $4000.0 in Q4 2025.
- Quarterly Other financing activities fell 98.92% year-over-year to $4000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $516000.0 (down 69.45% YoY) and the FY2025 annual result came in at $516000.0, down 69.45% from the prior year.
- Other financing activities fell to $4000.0 in Q4 2025 per CADL's latest filing, from $20000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $71.3 million in Q4 2021 and troughed at -$42000.0 in Q2 2021.
- A 4-year average of $5.3 million and a median of $90000.0 in 2021 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2021 and 2022: Other financing activities soared 245762.07% in 2021, then sank 99.95% in 2022.
- Over 4 years, Other financing activities stood at $71.3 million in 2021, then plunged by 99.95% to $36000.0 in 2022, then surged by 927.78% to $370000.0 in 2024, then sank by 98.92% to $4000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $4000.0, $20000.0, and $246000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,000.00 |
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 246,000.00 |
| Jun 30, 2025 | 246,000.00 |
| Mar 31, 2025 | 246,000.00 |
| Mar 31, 2025 | 246,000.00 |
| Dec 31, 2024 | 370,000.00 |
| Dec 31, 2024 | 370,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Mar 31, 2024 | 226,000.00 |
| Dec 31, 2022 | 36,000.00 |
| Dec 31, 2022 | 36,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Jun 30, 2022 | 22,000.00 |